Natural killer and CAR-NK cell therapies in urological cancers: Progress, mechanistic lessons from CAR-T, and future directions - PubMed
6 days ago
- #CAR-NK
- #Urologic cancers
- #Immunotherapy
- Review of NK and CAR-NK cell therapies for urological cancers (renal cell carcinoma, bladder cancer, prostate cancer).
- NK cells offer advantages like 'missing-self' recognition and ADCC, with lower risks of cytokine release syndrome and graft-versus-host disease compared to CAR-T cells.
- Coverage of conventional NK strategies, CAR-NK engineering to tackle the immunosuppressive tumour microenvironment, and preclinical/clinical advances with antigens like CAIX, CD70, PSMA, and nectin-4.
- CAR-NK therapy is a promising 'off-the-shelf' modality, but success in solid tumours depends on solving challenges like in vivo persistence, tumour homing, and resistance to immunosuppression.